ADS Biotec, a global manufacturer of automated instruments and laboratory reagents, has recently come up with two new Covid-19 tests and a very effective technique for mRNA purification, which is used for vaccine manufacturing. We talked to Stavros Papadimitriou, Vice-President of Marketing and Director of European Sales, to find out more about these products and understand what the pandemic has changed not only for his company but also for the laboratory industry in general as well as the next vaccine generations and relationships with China.
MedicalExpo e-magazine: What are the main products that you showcased at the last MEDICA event and which are your top products right now?
Stavros Papadimitriou: We are offering several SARS-Cov-2 solutions. Our new rapid antibody test is designed to monitor the level of antibodies over time after vaccination, in addition to detecting antibodies after infection. We published a white paper on this subject following a comparison study in a hospital in Germany with a competitor’s kit. In the end, we had a much better detection rate. Our rapid antigen test is based on the Colloidal Gold Method used for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen (SARS-CoV-2 N-antigen) providing the highest sensitivity. In summary, the new rapid antibody test is post-infection and post-vaccination, while the rapid antigen test is to see if you have been infected with Covid-19. Both products are CE-IVD and registered on the German BfArM portal. They are available in pharmacies and they both have 99 percent accuracy. The antigen test is taken through a nasal swab, the antibody test is through a blood test.
Regarding the new rapid antibody test, the innovation is that it is also designed for people who are vaccinated?
For More Information: